Eris Lifesciences Ltd (NSE:ERIS) Q2 FY23 Earnings Concall dated Oct. 20, 2022 Corporate Participants: Krishnakumar Vaidyanathan -- Executive Director and Chief Operating
Eris Lifesciences Ltd (ERIS) Q2 FY23 Earnings Concall Transcript
Categories
Health Care
ICICI Lombard General Insurance Company Limited (ICICIGI) Q2 FY23 Earnings Concall Transcript
ICICI Lombard General Insurance Company Limited (NSE: ICICIGI) Q2 FY23 Earnings Concall dated Oct. 18, 2022 Corporate Participants: Bhargav Dasgupta -- Managing
Everything you need to know about Jubilant Pharmova
About Company and its Outlook: Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research
Jubilant Pharmova reports dip in its net profit by 71% for Q1FY23
Jubilant Pharmova reported total income of INR 1,452 crores during the period ended June 30, 2022 as compared to INR 1,635 crores
Panacea Biotech Q1FY23 Net profit soars by 2%
Panacea Biotec reported total income of INR 111 crores during the period ended June 30, 2022 as compared to INR 132 crores
Decoding Panacea Biotec Limited: India’s leading Vaccine Developer
Summary: Universal Immunization Program (UIP) in India is one of the largest public health programs in the world. It targets vaccinating ~30.4
Balaxi Pharmaceuticals Ltd Q1 FY23 Earnings Conference Call Insights
Key highlights from Balaxi Pharmaceuticals Ltd (BALAXI) Q1 FY23 Earnings Concall Q&A Highlights: [00:06:25] Archana Gude with IDBI asked about the sustainable
SMS Pharmaceuticals Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/G2_d7tTye3s Key highlights from SMS Pharmaceuticals Limited (SMSPHARMA) Q1 FY23 Earnings Concall Q&A Highlights: Atul Kothari from Progwell Securities asked about the
Top 5 Stocks with 200% Profit Growth in 2022
1. India Cements Ltd India Cements Ltd is a leading cement manufacturing company based in Chennai. It was founded in 1946 by
Gufic Biosciences Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/l4VNZKKcWGw Key highlights from Gufic Biosciences Limited (GUFICBIO) Q1 FY23 Earnings Concall Q&A Highlights: Girish Gulati asked about pancreatic cancer update and
Aurobindo Pharma Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/b8g7f6BUs9Y Key highlights from Aurobindo Pharma Limited (AUROPHARMA) Q1 FY23 Earnings Concall Q&A Highlights: [00:08:34] Prakash Agarwal of Axis Capital asked about
Shilpa Medicare Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/4rB2G3iK3UE Key highlights from Shilpa Medicare Ltd (SHILPAMED) Q1 FY23 Earnings Concall Q&A Highlights: Vineet Gala of Monarch Networth asked about the
Marksans Pharma Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/9PAJ7vTTG5E Key highlights from Marksans Pharma Limited (MARKSANS) Q1 FY23 Earnings Concall Management Update: MARKSANS said it aims to increase its R&D
Zydus Lifesciences Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/R4mbpNYrIhE Key highlights from Zydus Lifesciences Ltd (ZYDUSLIFE) Q1 FY23 Earnings Concall Q&A Highlights: Neha enquired about the drivers of strong growth
Supriya Lifescience Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/LNBcyeiXX0U Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q1 FY23 Earnings Concall Management Update: SUPRIYA said the company is extending its backward
Balaxi Pharmaceuticals Ltd (BALAXI) Q1 FY23 Earnings Concall Transcript
Balaxi Pharmaceuticals Ltd (NSE:BALAXI) Q1 FY23 Earnings Concall dated Aug. 18, 2022 Corporate Participants: Ashish Maheshwari -- Managing Director Pranav Maheshwari --
SMS Pharmaceuticals Limited (SMSPHARMA) Q2 FY23 Earnings Concall Transcript
SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Q2 FY23 Earnings Concall Aug. 18, 2022 Corporate Participants: P. Vamsi Krishna -- Executed Director LakshminarayanaTammineedi -- Chief
Apollo Hospitals research report at a glimpse
Stock Data: TickerAPOLLOHOSPExchangeBSE and NSE IndustryHealthcare Why is the stock price rising? Shares of Apollo Hospitals Enterprise Ltd have gained 8.84% over the
Apollo Hospitals Enterprise Limited Q1 FY23 Earnings Conference Call Insights
https://youtu.be/niPJDB-NX_Y Key highlights from Apollo Hospitals Enterprise Limited (APOLLOHOSP) Q1 FY23 Earnings Concall Q&A Highlights: Nitin Gosar from Invesco asked about the
Divi’s Laboratories Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/EPaxfKgyoZQ Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Q&A Highlights: Tushar Manudhane from Motilal Oswal asked about the
Apollo Hospitals Enterprise Limited Q1FY23; 35% fall in Profits
Revenue for Q1 FY23 has increased by 1% YoY to ₹ 37,956 millions. Profits have fallen by 35% YoY to ₹ 31,711